AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$GKOS

Navratil Tomas sold $2.5M of GKOS

Navratil Tomas (CHIEF DEVELOPMENT OFFICER) sold 13,744 shares of GLAUKOS Corp (GKOS) at an average of $180.67 ($180.25–$182.50, $2.48M total) across 3 trades on 2026-08-28.

Original reporting
SEC EDGAR · Navratil Tomas
Published Sep 1, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 7:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GKOS
Bearish
medium confidence
Mentioned
$GKOS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GKOSBearishLow
01

Why it matters

Provides fresh, primary data on insider activity, useful for short-term traders.

02

Market read

Insider sale adds modest negative pressure on GKOS stock.

03

What to watch

No 10b5-1 plan; sale may be unrelated to company fundamentals.

Relevance 6/10Novelty 5/10Timing: post-market 2026-08-28

Background

SEC Form 4 filing discloses insider transactions for public companies.

Company-level read

Ticker impact

$GKOSBearishMedium confidence
Context

Chief Development Officer Navratil Tomas sold 13,744 shares for $2.48M on 2026-08-28.

Expected impact

possible short-term downside pressure

Evidence & confidence

Sale size is modest but notable for a small-cap; insider is a senior officer.

Market effects

Sector

Minimal impact on the broader biotech sector.

Regional

Limited to U.S. small-cap investors.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Glaukos Corp

    US-listed ophthalmic medical device company (ticker GKOS).

  • Insider
    Navratil Tomas

    Chief Development Officer of Glaukos Corp.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GKOS insider trading history →

Related articles

AUG 25
$GKOSHighAI 8/10

Glaukos Market Cap More Than Doubles in a Year to $11B

Glaukos Corp.'s market cap has more than doubled to $11 billion in a year, driven by expanding into new eye care markets and record Q2 sales of $185.6 million. The company raised its full-year guidance and saw its shares rise over 15% post-earnings. Key products include iDose TR for glaucoma and Epioxa for keratoconus, with several other products in development.

ocbj.com2 min
AUG 20
$GKOSMed

GKOS Stock Surges 67% Year to Date: What's Driving the Rally?

Glaukos (GKOS) shares have risen 67.9% year-to-date, driven by strong revenue growth and product launches. Q2 revenue increased 49.5% to $185.6M, prompting raised 2026 guidance to $680-700M. Growth is attributed to iDose TR and Epioxa, with international expansion and a broad pipeline also contributing. Competitors include Alcon (ALC), Sight Sciences (SGHT), and AbbVie (ABBV). Risks include reimbursement and competition.

tradingview.com2 min
AUG 20
$GKOSMedAI 8/10

Glaukos Corp stock hits all-time high at 190.27 USD

Glaukos Corp (GKOS) hit an all-time high of $190.27, with a 111.6% increase over the past year. Its market cap is $11.03 billion, and revenue grew 41.55% over the last twelve months. Q2 2026 revenue was $185.6 million, up 49.5% year-over-year, exceeding estimates. Analysts raised price targets, with Truist Securities setting it at $215.

investing.com2 min
AUG 8
$GKOSMedAI 8/10

Glaukos (GKOS) Q2 2026 Earnings Call Transcript

Glaukos (NYSE: GKOS) reported Q2 2026 net sales of $185.6 million, up 50% year over year. U.S. glaucoma sales were $118.5 million, and iDose TR revenue was about $74 million. The company raised full-year 2026 net sales guidance to $680 million to $700 million and iDose TR revenue guidance to $275 million to $280 million.

aol.com7 min